Orum Therapeutics

Orum Therapeutics is a biotech company listed on KOSDAQ, Korea's tech-focused stock exchange, that develops experimental cancer medicines designed to destroy disease-causing proteins inside specific cells.

Its core platform, which it calls DAC (Degrader-Antibody Conjugate), combines two established drug-design approaches: the precise cell-targeting ability of antibody-drug conjugates and the protein-destroying mechanism of targeted protein degradation. The company's pipeline is built entirely around this proprietary dual-precision technology, which it applies across multiple disease areas.